Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, CA 90095, USA.
Cell. 2018 May 31;173(6):1316-1317. doi: 10.1016/j.cell.2018.05.030.
Chimeric antigen receptor (CAR) T cells offer a promising treatment option for advanced cancers resistant to standard therapy. Here, Cho et al. report a split-CAR design that enables the engineering of multi-feature CAR-T cells, aiming to address current challenges limiting the safety and efficacy of CAR-T cells for cancer treatment.
嵌合抗原受体 (CAR) T 细胞为对标准治疗耐药的晚期癌症提供了一种有前途的治疗选择。在这里，Cho 等人报告了一种分裂 CAR 设计，该设计能够对多功能 CAR-T 细胞进行工程改造，旨在解决目前限制 CAR-T 细胞治疗癌症的安全性和有效性的挑战。
